Hallmark tumor metabolism becomes a validated therapeutic target

Abstract

Altered cell metabolism has long been recognized as a distinctive feature of malignant cells but, until recently, research e orts had focused on a single aspect. It has become increasingly evident that many metabolic pathways are altered in cancer cells. Improved understanding has yielded the rst regulatory approval in this new class of drugs. Here, we discuss the latest developments in the therapeutic targeting of the cancer metabolism hallmark.